ResMed (RMD) Tops Q4 EPS by 25c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
ResMed (RMD) PT Raised to $212 at Oppenheimer
August 6, 2020 8:14 AM EDTOppenheimer analyst Suraj Kalia raised the price target on ResMed (NYSE: RMD) to $212.00 (from $200.00) while maintaining an Outperform rating.
The analyst commented, "ResMed reported 4Q20 revenue slightly higher than consensus estimate at $752M, and roughly in line with our $770M estimate. Pull-through... More
